Pyrimethamine 3D printlets for pediatric toxoplasmosis: design, pharmacokinetics, and anti-toxoplasma activity

• Published in: Expert opinion on drug delivery Vol. 20; no. 2; p. 301
• Main Authors: Rahman, Ziyaur, Khuroo, Tahir, Mohamed, Eman M, Dharani, Sathish, Kayalar, Canberk, Kuttolamadom, Mathew A, Sangaré, Lamba Omar, Khan, Mansoor A
• Format: Journal Article
• Language: English
• Published: England 01-02-2023
• Subjects: Child; Excipients - chemistry; Humans; Povidone; Pyrimethamine - therapeutic use; Solubility; Tablets - chemistry; Toxoplasma; Toxoplasmosis; printlets; anti-toxoplasma activity; pharmacokinetic; Pyrimethamine; dissolution; phase transformation
• ISSN: 1744-7593
• DOI: 10.1080/17425247.2023.2169272

The focus of the present research is to develop printlet formulations of pyrimethamine (PMT).
Printlets formulation of PMT were developed by screening design by varying laser scanning speed, Kollidon® VA 64, polyvinylpyrrolidone, and disintegrant.
Laser scanning speed, Kollidon® VA, and disintegrant had statistically significant effect on hardness, disintegration time, and/or dissolution (p < 0.05). Dissolution was almost 100% in 30 min. X-ray powder diffraction indicated partial amorphous transformation of the crystalline drug. Pharmacokinetic and anti-toxoplasma activity profiles of the printlets and compressed tablets were superimposable with no statistical difference (p > 0.05).
Clinical performance of the printlets would be similar to the compressed tablets.